Search

Your search keyword '"Eliazar Sabater Cabrera"' showing total 7 results
Start Over Author "Eliazar Sabater Cabrera"
7 results on '"Eliazar Sabater Cabrera"'

1. Quantifying Stated Preferences for Meningococcal Vaccines Among Adolescents/Young Adults and Parents of Adolescents in the United States: A Discrete Choice Experiment

Author

Shahina Begum, Eliazar Sabater Cabrera, Oscar Herrera Restrepo, Cindy Burman, Woo-Yun Sohn, Elise Kuylen, Hiral Shah, and Zeki Kocaata

Subjects
Discrete choice experiment, Invasive meningococcal disease, Meningococcal vaccination, Patient preference, Infectious and parasitic diseases, RC109-216
Abstract

Abstract Introduction Invasive meningococcal disease (IMD) is a severe and life-threatening disease. In the United States (US), vaccine coverage with MenACWY and MenB meningococcal vaccines is suboptimal among adolescents/young adults aged 16–23 years. A combined meningococcal vaccine (MenABCWY) could increase convenience (e.g., fewer injections) and improve coverage. The objective was to quantify preferences for hypothetical meningococcal vaccine profiles among adolescents/young adults and parents. Methods An online discrete choice experiment was conducted among 16- to 23-year-olds, and parents of 16- to 18-year-olds. Attributes (3 × 4) and levels (1 × 2) were based on the literature and focus groups. Participants made ten pair-wise forced trade-off choices, systematically varied using a D-optimal design. Random parameter logit quantified the relative importance of vaccination attributes and estimated the trade-offs. Differences in preferences by subgroups were assessed. Results Totals of 300 adolescents and young adults (median age 20 years) and 300 parents (median age 46 years) completed the survey. Overall, 89.6% of 16- to 23-year-olds and 69.1% of parents preferred a simplified hypothetical meningococcal vaccination profile, e.g., with fewer injections (3 vs. 4) and fewer healthcare provider (HCP) visits (2–3 vs. 4). Having HCP advice and clear Centers for Disease Control and Prevention recommendations impacted vaccination choice, with both groups reporting high trust in HCP information (83.3% among 16- to 23-year-olds; 98.7% among parents). Barriers to vaccination included lack of HCP advice or awareness of meningococcal vaccines, and income level and out-of-pocket costs for parents. Conclusions Adolescents/young adults and parents demonstrated a significant preference for a meningococcal vaccine that is more convenient (such as combined MenABCWY). Parents’ vaccination preferences differed by income level and out-of-pocket costs, suggesting financial barriers to vaccination may exist which could result in IMD prevention inequalities. Findings from this study provide important information to support patient-facing informed policy discussions. A simplified vaccination schedule and strong recommendation could help improve vaccine uptake, schedule compliance, disease prevention, and reduce inequalities in IMD risk and prevention. A graphical abstract is available with this article. Graphical Abstract

Published
2024
Full Text
View/download PDF

2. Patient-reported outcomes in vaccines research: relevance for decision-making

Author

Desmond Curran, Eliazar Sabater Cabrera, and Linda Nelsen

Subjects
patient-reported outcomes, comparative effectiveness, electronic pro, health technology assessment, clinical outcomes assessments, health-related quality of life, qualitative research, pro instruments, public health benefit, vaccines, Immunologic diseases. Allergy, RC581-607, Therapeutics. Pharmacology, RM1-950
Abstract

The development and demand for effective vaccines have witnessed an exponential growth over the last century. In the meantime, the vaccine market involves more knowledgeable stakeholders, with a shift in emphasis by regulatory agencies on understanding the patient perception and experience. The Food and Drug Administration’s publication of the patient-reported outcomes (PRO) guidance has elevated the discipline of PROs and has resulted in a transition from clinician reports of patient outcomes to PROs. This review reports various research methods, which utilize PROs, including qualitative and quantitative research, clinical trials, and patient preference studies. With the advancement of electronic PRO data capture, additional advantages of PROs are being observed and utilized (e.g. as a trigger for clinical endpoints). We discuss uses and advantages of including PROs into the clinical trial program to improve efficiencies, clinical relevance and overall validity of the program in the vaccine field. (See Plain Language Summary)

Published
2022
Full Text
View/download PDF

4. Study to determine relevant health outcome measures in opioid use disorder: multicriteria decision analysis

Author

Joan Colom, Nestor Szerman, Eliazar Sabater Cabrera, Francisco Ferre, Francisco Pascual, Antoni Gilabert-Perramon, Miguel Ángel Casado, Julio Bobes, Grupo de Trabajo MCDA-OUD, [Colom J] Sub-direcció General de Drogodependències, Secretaria de Salut Pública, Departament de Salut, Generalitat de Catalunya, Barcelona, Spain. Programa de prevenció, control i atenció al VIH, les ITS i les HV, Agència de Salut Pública de Catalunya (ASPCAT), Departament de Salut, Generalitat de Catalunya, Barcelona, Spain. [Szerman N] Fundación Patología Dual, Madrid, Spain. Servicio de Salud Mental Retiro, Hospital Universitario Gregorio Marañón, Madrid, Spain. [Sabater E, Casado MA] Pharmacoeconomics & Outcomes Research Iberia (PORIB), Madrid, Spain. [Ferre F] Servicio de Psiquiatría, Hospital Gregorio Marañón, Madrid, Spain. Estrategia de Salud Mental, Sistema Nacional de Salud, Ministerio de Sanidad, Madrid, Spain. [Pascual F] Socidrogalcohol, Barcelona, Spain. Unidad de Conductas Adictivas, Alicante, Spain. [Gilabert-Perramon A] Àrea de Farmàcia i del Medicament, Consorci Social i de Salut de Catalunya, Barcelona, Spain. Universidad de Barcelona, Barcelona, Spain. [Bobes J] Sociedad Española de Psiquiatría, Madrid, Spain. Universidad de Oviedo, Oviedo, Spain, and Departament de Salut

Subjects
medicine.medical_specialty, terapéutica::farmacoterapia::tratamiento de sustitución de opiaceos [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], localizaciones geográficas::Europa (continente)::España [DENOMINACIONES GEOGRÁFICAS], business.industry, Antisocial personality disorder, Medicine (miscellaneous), Opioid use disorder, medicine.disease, Comorbidity, Psychiatry and Mental health, Geographic Locations::Europe::Spain [GEOGRAPHICALS], Quality of life (healthcare), Abús de substàncies - Espanya, Medicine, Attention deficit hyperactivity disorder, Opiacis, business, Psychiatry, Borderline personality disorder, Psychosocial, Anxiety disorder, Therapeutics::Drug Therapy::Opiate Substitution Treatment [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT]
Abstract

Trastorno por consumo de opiáceos; Programas de tratamiento de sustitución de opiáceos; Análisis de decisión multicriterio Trastorn per consum d'opiacis; Programes de tractament de substitució d'opiacis; Anàlisi de decisió multicriteri Opioid use disorder; Opioid substitution programmes; Multicriteria decision analysis El objetivo fue establecer los resultados en salud con mayor relevancia en la evaluación de programas de tratamiento de sustitución de opiáceos (PTSO) en pacientes con trastorno por consumo de opiáceos (TCO) en España. Se realizó un análisis de decisión multicriterio con 3 fases: 1) definición de conceptos y criterios a evaluar; 2) cribado y ponderación de criterios mediante un experimento de elecciones discretas; 3) proceso deliberativo. Los criterios de la fase 1 fueron: consumo de sustancias (opiáceos, alcohol, tabaco, estimulantes y cannabis), trastornos mentales (trastorno afectivo ansioso, psicosis, trastorno por déficit de atención e hiperactividad, trastorno límite de personalidad, trastornos de personalidad antisocial, trastorno por juego y otras alteraciones del control de los impulsos), nivel de discapacidad, adherencia, enfermedades médicas (comorbilidades, conductas de riesgo, enfermedades infecciosas y de transmisión sexual), aspectos psicosociales (conducta hostil y/o violenta, presencia de problemas laborales), discapacidad funcional (calidad de vida, satisfacción con el tratamiento y servicio, funcionamiento social). En la fase 2 se determinaron los factores fundamentales en la elección de un PTSO, revisados en el proceso deliberativo: remisión del consumo de sustancias (opiáceos, alcohol y estimulantes), mejoría en el manejo de otros trastornos mentales (psicosis y trastorno límite de la personalidad), mejoría en manejo de comorbilidades médicas y mejoría en el funcionamiento social, con un peso del 56,5%, 21,9%, 11,0% 10,7% respectivamente. Este análisis define los resultados sanitarios más relevantes en PTSO en pacientes con TCO en España, favoreciendo la toma de decisiones y la gestión socio-sanitaria de los recursos existentes. The aim of the current study was to establish the most relevant health outcomes to assess opioid substitution treatment programmes (OSP) in patients with opioid use disorder (OUD) in Spain. A multicriteria decision analysis was applied in 3 phases: 1) concepts and criteria definitions; 2) criteria screening and weighting by means of a discrete choice experiment; 3) deliberative process. Criteria established in phase 1 were: substance use (opioids, alcohol, tobacco, stimulants and cannabis), other mental disorders (affective/anxiety disorder, psychosis, attention deficit hyperactivity disorder, borderline personality disorder, antisocial personality disorder, gambling disorder and other impulse control disorders), level of disability, adherence, medical illnesses (medical comorbidities, risk behaviours, infectious and sexually transmitted diseases), psychosocial aspects (hostile and/ or violent behaviour and work problems), functional disability (quality of life, treatment and service satisfaction, social functionality). In phase 2, the most relevant factors in OSP were determined, and subsequently assessed in the deliberative process: remission of substance use (opioids, alcohol and stimulants), improvement of other mental disorders (psychosis and borderline personality disorder), improvement in comorbidity management, and improvement in social functionality, with a weighting of 56.5%, 21.9%, 11.0%, and 10.7%, respectively. The current analysis defines the main health outcomes in OSP in patients with OUD in Spain, supporting decision making and socio-health management of existing resources.

Published
2021

5. 23. ZOE-50 and ZOE-70 Placebo Groups Data Shows that Burden of Pain Associated with Herpes Zoster Interferes with Activities of Daily Living

Author

Eliazar Sabater Cabrera, Desmond Curran, Sean Matthews, Céline Boutry, Nicolas Lecrenier, and Anthony L Cunningham

Subjects
Infectious Diseases, Oncology
Abstract

Background Adults ≥ 50 years of age (YOA) are at increased risk of herpes zoster (HZ), a condition which can cause long-term pain and discomfort. In this analysis, we assessed the burden of pain associated with HZ and its interference with activities of daily living (ADL) in patients ≥ 50 YOA. Methods ZOE-50 (NCT01165177) and ZOE-70 (NCT01165229) were phase III, observer-blind, placebo-controlled, 1:1 randomized studies in adults ≥ 50 YOA (ZOE-50) and ≥ 70 YOA (ZOE-70) who received 2 doses of the adjuvanted recombinant zoster vaccine or placebo, 2 months apart. To correctly evaluate HZ pain, the analysis was performed only on the placebo groups data of ZOE-50 (≥ 50 YOA) and pooled ZOE-50/70 (≥ 70 YOA pooled data) in the modified total vaccinated cohort (mTVC, primary population for efficacy analysis) HZ-confirmed cases. HZ pain and interference with ADL was assessed by the Zoster Brief Pain Inventory (ZBPI) instrument completed daily by patients for the first 28 days and then weekly until resolution. Time to resolution of clinically significant pain was analyzed using Kaplan Meier methods. We estimated the cumulative area under curve (AUC) of the ZBPI worst pain score and the ZBPI ADL score up to 182 days post-HZ rash onset. A high AUC reflects a higher severity/longer duration of pain. Results Overall, 254 patients ≥ 50 YOA and 284 patients ≥ 70 YOA were included in the mTVC HZ-confirmed cases for the ZOE-50 and ZOE-70 pooled analysis, respectively. In HZ patients ≥ 50 YOA, 94.6% reported any pain (ZBPI pain score > 0), 87.6% clinically significant pain (ZBPI pain score ≥ 3) and 65.1% severe pain (ZBPI pain score ≥ 7). Similarly, in HZ patients ≥ 70 YOA, 93.2% reported any pain, 90.9% clinically significant pain and 68.4% severe pain. It was estimated that 11.6% and 18.3% of patients aged ≥ 50 and ≥ 70 YOA, respectively, had clinically significant pain 3 months after the onset of HZ. The mean AUC at 182 days was 137.24 (≥ 50 YOA) and 190.68 (≥ 70 YOA), for the ZBPI worst pain score and 92.75 (≥ 50 YOA) and 130.89 (≥ 70 YOA), for the ZBPI ADL score. Conclusion Analysis of data provided by patients with confirmed HZ shows that the burden of HZ pain is high and is associated with interference on patients’ ADL. Funding GlaxoSmithKline Biologicals SA Acknowledgment M Maior/S Hulsmans provided medical writing/editorial support (Modis c/o GSK) Disclosures Eliazar Sabater Cabrera, MSc, GSK (Employee, Shareholder) Desmond Curran, PhD, The GSK group of companies (Employee, Shareholder) Sean Matthews, MSc, GSK (Independent Contractor) Céline Boutry, PhD, GSK (Employee) Nicolas Lecrenier, Ing, PhD, The GSK group of companies (Employee, Shareholder) Anthony L. Cunningham, F.A.H.M.S., MD, M.B.B.S., B. Med. Sci. (Hons), F.R.A.C.P., F.R.C.P.A., F.A.S.M., GSK group of companies (Grant/Research Support, Advisor or Review Panel member, Speaker’s Bureau)

Published
2021

6. Análisis coste-utilidad de valganciclovir durante 200 días frente a 100 días post-trasplante como tratamiento preventivo de la enfermedad por citomegalovirus en receptores de trasplante renal de alto riesgo

Author

Cristina Varela, Eliazar Sabater-Cabrera, Elena Ruiz-Beato, Julián Torre-Cisneros, Constantino Fernández-Rivera, and Lluis Guirado-Perich

Subjects
Health Policy, Pharmacology, Toxicology and Pharmaceutics (miscellaneous)
Abstract

Estimar la relacion coste-utilidad de valganciclovir durante 200 dias (VGC 200) frente a valganciclovir durante 100 dias (VGC 100) en pacientes que han recibido un trasplante renal de alto riesgo (TRAR) D+/R−, desde la perspectiva del Sistema Nacional de Salud (SNS) en Espana. Se desarrollo un modelo de Markov para simular la historia natural de la progresion de la enfermedad por citomegalovirus en una cohorte de 10.000 pacientes durante 10 anos. Los datos de la enfermedad se obtuvieron del ensayo IMPACT (ano 1) y de la mejor evidencia cientifica disponible (anos 2–10). Los costes unitarios (€ de 2010) se obtuvieron del Catalogo de Medicamentos y de la base de datos e-Salud. Los valores de utilidad se tomaron de la literatura. Se aplico una tasa de descuento del 3 % para costes y resultados. Los resultados se expresaron como coste incremental de VGC 200 frente a VGC 100 por ano de vida ajustado por calidad (AVAC) ganado. Se realizo un analisis de sensibilidad (AS) univariante y multivariante. VGC 200 proporciona mejores resultados que VGC 100 (5,002 AVAC frente a 4,764 AVAC; 0,238 AVAC ganados por paciente). El coste promedio por paciente fue de 109.012,11 € con VGC 200 y de 110.305,14 € con VGC 100 (ahorro de costes de 1.293,03 € por paciente). Los resultados del AS muestran la robustez del analisis. La administracion de VGC 200 dias frente a VGC 100 dias en pacientes que han recibido un TRAR D+/R− es una estrategia eficiente desde la perspectiva del SNS en Espana.

Published
2013

Catalog

Books, media, physical & digital resources
See catalog results